Do you need Gilteritinib Intermediates solution? Choose us as your partner and we will provide you with a solution that will satisfy you.
Molecular Formula
C62H92N16O10
Molecular Weight
1221.5
g/mol
InChI Key
UJOUWHLYTQFUCU-WXXKFALUSA-N
FDA UNII
5RZZ0Z1GJT
Gilteritinib Fumarate is the fumarate salt form of gilteritinib, an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.
Want more information on Gilteritinib Intermediates? Click the link below to contact us.